| Autor: |
Thijs, L., Amery, A., Antikainen, R., Bert, P., Birkenhäger, W., Bulpitt, C. J., Dollery, C. T., Fletcher, A. E., Forette, F., Hakamäki, T., Kivinen, P., Lehtomaki, E., O'brien, E., Sarti, C., Staessen, J., Tilvis, R., Trimarco, B., Tuomilehto, J., Vanhanen, H., Vänska, O., Webster, J., Yodfat, Y. |
| Zdroj: |
Clinical and Experimental Hypertension; 1993, Vol. 15 Issue: 6 p953-966, 14p |
| Abstrakt: |
The Syst-Eur trial is a randomised, double-blind, placebo-controlled trial that examines the hypothesis that antihyper-tensive treatment can prevent or delay cardiovascular complications in elderly patients (> 60 years) with isolated systolic hypertension. On March, 1st 1993 a total of 1395 patients with a sitting systolic blood pressure on placebo averaging 160-219 mmHg and a diastolic blood pressure < 95 mmHg were randomised into this trial. The placebo and active treatment groups were similar at randomisation with respect to age (7 2 ±7 years, mean ± SD), percentage of women (68%), percentage of patients with cardiovascular complications (30%) and sitting blood pressures (175±12/85±6 mmHg). The fall in sitting systolic and diastolic blood pressures from baseline to 2 years was significantly more pronounced (p<0.001) in the actively treated (-22±18/-6±9 mmHg) as compared with the placebo treated Syst-Eur patients (-10±20/- 1±9 mmHg). Active treatment consists of nitrendipine if necessary associated with a converting-enzyme inhibitor and a thiazide. Whether treatment with these antihypertensive agents results in a clinically meaningful reduction of cardiovascular morbidity and mortality is the subject of investigation in this trial. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
